Coloplast ASCLPBF 72 Forward PE Ratio is 15.13 as of Jul. 12, 2026. GuruFocus rates CLPBF with a GF Score™ of 72/100 and a GF Value™ of $126.15 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 392 Medical Devices & Instruments companies, Coloplast AS ranks better than 65.82% on this metric.
Coloplast AS's Forward PE Ratio for today is 15.13.
Coloplast AS (OTCPK:CLPBF) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Coloplast AS Forward PE Ratio Related Terms
Coloplast AS Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Coloplast AS's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coloplast AS Forward PE Ratio Chart
Coloplast AS Annual Data
Trend
2016-09
2017-09
2018-09
2019-09
2020-09
2021-09
2022-09
2023-09
2024-09
2025-09
Forward PE Ratio
26.53
24.88
31.06
36.63
41.84
40.16
27.10
28.17
33.00
21.01
Coloplast AS Quarterly Data
2015-12
2016-03
2016-06
2016-09
2016-12
2017-03
2017-06
2017-09
2017-12
2018-03
2018-06
2018-09
2018-12
2019-03
2019-06
2019-09
2019-12
2020-03
2020-06
2020-09
2020-12
2021-03
2021-06
2021-09
2021-12
2022-03
2022-06
2022-09
2022-12
2023-03
2023-06
2023-09
2023-12
2024-03
2024-06
2024-09
2024-12
2025-03
2025-06
2025-09
2025-12
2026-03
Forward PE Ratio
31.06
24.75
25.97
26.53
24.75
27.93
28.01
24.88
26.46
27.62
32.26
31.06
28.82
35.34
32.89
36.63
38.31
42.74
42.02
41.84
41.32
42.55
39.22
40.16
45.45
37.45
26.46
27.10
30.67
35.46
30.49
28.17
31.06
37.31
30.12
33.00
29.65
28.50
21.24
21.01
20.26
16.88
CLPBF vs ISRG, BDX, MDLN: Forward PE Ratio Comparison
For the Medical Instruments & Supplies subindustry, Coloplast AS's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coloplast AS Forward PE Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Coloplast AS's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Coloplast AS's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Coloplast AS (CLPBF) has a Forward PE Ratio of 15.13 as of Jul. 12, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Coloplast AS and its competitors. According to the industry distribution chart, Coloplast AS ranks #134 out of 392 companies in the Medical Devices & Instruments industry, placing it in the top 34.2%.
Is Coloplast AS's Forward PE Ratio too high?
Coloplast AS's current Forward PE Ratio is 15.13. The Medical Devices & Instruments industry median Forward PE Ratio is 19.14. Coloplast AS's value of 15.13 is 21% below this industry median. Based on the distribution chart, Coloplast AS ranks #134 out of 392 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Coloplast AS has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Coloplast AS's Forward PE Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Coloplast AS ranks #134 out of 392 companies for Forward PE Ratio. This puts Coloplast AS in the upper half of its industry. The industry median Forward PE Ratio is 19.14. Coloplast AS's value of 15.13 is 21% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Medical Devices & Instruments company?
The median Forward PE Ratio among Medical Devices & Instruments companies is 19.14, based on 392 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Coloplast AS's current Forward PE Ratio of 15.13 is 21% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Coloplast AS and its competitors. For the Medical Devices & Instruments industry, the median Forward PE Ratio is 19.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coloplast AS's current Forward PE Ratio is 15.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coloplast AS stock overvalued right now?
Based on GuruFocus' analysis, Coloplast AS (CLPBF) is currently considered Significantly Undervalued. The stock's GF Value™ is $126.15, compared to a current price of $61.76 — trading 51% below its estimated fair value. The current Forward PE Ratio is 15.13 and 21% below the Medical Devices & Instruments industry median of 19.14. Coloplast AS's overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Coloplast AS (CLPBF), the current Forward PE Ratio is 15.13 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coloplast AS (CLPBF) Overvalued in 2026?
Based on GuruFocus' analysis, Coloplast AS stock appears to be undervalued.
The current stock price of $61.76 is trading 51% below its estimated GF Value™ of $126.15.
GuruFocus considers Coloplast AS to be Significantly Undervalued.
Key valuation signals for CLPBF:
Forward PE Ratio: 15.13
GF Value™: $126.15 vs. price of $61.76 (51% below fair value)
Industry Position: 21% below the Medical Devices & Instruments median (#134 of 392)
No single metric tells the full story. See the CLPBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, intermittent catheters for continence care, and devices for patients with neck stomas. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
72GF Score
Get the complete analysis for CLPBF
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLPBF has been successfully added to your 